Race Oncology has announced it has secured a new patent on its cancer drug, Zantrene®, from the United States Patent and Trademarks Office (USPTO). This is Race’s third patent granted on Zantrene in the United States.
“The new US patent allows additional claims around the use of Bisantrene in combination with other drugs for treating cancer,” said Race CEO Peter Molloy.
“Given that most cancer treatments employ combination regimens, we believe these new claims significantly bolster the attractiveness of Bisantrene to commercial partners.”
The new patent covers expanded uses of Zantrene, in particular its use in combination with other cancer drugs to treat Acute Myeloid Leukaemia (AML) and breast cancer.
This includes the use of Zantrene in combination with cytarabine, hypomethylating agents (for example, azacitidine and decitabine), checkpoint inhibitors and other targeted immune therapies, as well as other classes of cancer drugs.
The new patent is the result of a divisional application following on from one of the Race’s previous Zantrene patents granted in 2018 in the US (US 9974774), which protected the use of Bisantrene in patients with refractory or relapsed cancers, including AML and related leukaemias, as well as breast cancer, lymphoma and other cancers.
The latest patent expands Zantrene’s protected use to combination therapies.